Meeting Banner
Abstract #2520

MRI/MRS monitoring of anti-tumor treatments in an in vivo orthotopic model of a mammary tumor cell line expressing the d16HER2 variant

Gianmauro Palombelli1, Egidio Iorio1, Giulia Carpinelli2, Martina Borghi3, Francesco Lozupone4, Tommaso Azzarito4, Manuela Iezzi5, Ada Koschorke6, Elda Tagliabue6, Serenella Pupa6, and Rossella Canese1

1Cell Biology and Neurosciences, Istituto Superiore di Sanita', Roma, Italy, 2Cell Biology and Neusciences, Istituto Superiore di Sanita', Rome, Italy, 3Infectious, Parasitic and Immune-mediate Diseases, Istituto Superiore di Sanita', Roma, Italy, 4Drug Research and Evaluation, Istituto Superiore di Sanita', Roma, Italy, 5Medicine and Aging Sciences, G. d'Annunzio University of Chieti-Pescara, Chieti, Italy, 6Experimental Oncology and Molecular Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy

The HER2 splice variant lacking exon-16 (d16HER2) has been detected in human breast carcinomas.It has been shown in proper transgenic mouse models that d16HER2 variant leads to an increased transforming potency compared to the wild-type (wt) HER2 receptor. In this work, a murine mammary carcinoma cell line transgenically expressing the human d16HER2 variant (MI6 cells)-was implanted in the mammary fat pad of parental FVB mice which were treated with lapatinib or phenethyl isothiocyanate (PEITC), respectively targeting HER2 receptor and breast cancer initiating cells , and analyzed by in vivo DWI and quantitative MRS analyses.

This abstract and the presentation materials are available to members only; a login is required.

Join Here